XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.1
SHARE-BASED COMPENSATION
3 Months Ended
Mar. 28, 2021
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation SHARE-BASED COMPENSATION
Stock Options

For the thirteen week periods ended March 28, 2021 and March 29, 2020, the Company recognized $0.1 million of compensation expense related to stock options. Unamortized share-based compensation expense as of March 28, 2021 amounted to $0.8 million which is expected to be recognized over the next 2.3 years.
 
A summary of stock option activity is presented as follows:
 Number of
Shares
Weighted Average Exercise Price Per ShareWeighted Average Remaining Contractual LifeTotal Intrinsic Value of Awards
(in thousands)
Options outstanding at December 27, 2020652,655 $17.63 7.1$665 
Exercised(600)$9.72 
Options outstanding at March 28, 2021652,055 $17.64 6.8$1,013 
Options exercisable at December 27, 2020416,717 $16.96 6.3$463 
Options exercisable at March 28, 2021429,067 $17.24 6.1$704 
 Number of
Shares
Weighted Average Grant Date Fair Value
Nonvested outstanding at December 27, 2020235,938 $18.83 
Nonvested outstanding at March 28, 2021222,988 $18.42 

For the thirteen week period ended March 28, 2021, the Company issued 213 shares of common stock upon the cashless exercise of 600 stock options.

Restricted Stock

For the thirteen week periods ended March 28, 2021 and March 29, 2020, the Company recognized $0.1 million of compensation expense related to restricted stock awards. Unamortized share-based compensation expense as of March 28, 2021 amounted to $0.3 million which is expected to be recognized over the next 2.3 years.

A summary of restricted stock activity is presented as follows:
 Number of
Shares
Weighted Average Grant Date Fair Value
Restricted outstanding at December 27, 202025,218 $16.01 
Issued7,518 $12.97 
Vested(1,878)$12.97 
Restricted outstanding at March 28, 202130,858 $15.45 
Nonvested outstanding at December 27, 202025,218 $16.01 
Nonvested outstanding at March 28, 202130,858 $15.45 

Warrant Activity
 
For the thirteen week periods ended March 28, 2021 and March 29, 2020, the Company did not recognize compensation cost related to warrants. There was no unamortized stock compensation expense to be recognized as of March 28, 2021.
 
A summary of warrant activity is presented as follows:
 Number of
Shares
Weighted Average Exercise Price Per ShareWeighted Average Remaining Contractual LifeTotal Intrinsic Value of Options
(in thousands)
Warrants outstanding at December 27, 202025,862 $16.80 0.4$— 
Warrants outstanding at March 28, 202125,862 $16.80 0.2$— 
Warrants exercisable at December 27, 202025,862 $16.80 0.4$— 
Warrants exercisable at March 28, 202125,862 $16.80 0.2$— 

There were no nonvested warrants outstanding at March 28, 2021 and December 27, 2020.

The intrinsic value in the tables above is the amount by which the market value of the underlying stock exceeded the exercise price of outstanding options or warrants, before applicable income taxes and represents the amount holders would have realized if all in-the-money options or warrants had been exercised on the last business day of the period indicated.
2020 Employee Stock Purchase Plan (“2020 ESPP”)In November 2020, the Company's shareholders approved the 2020 ESPP. Under the 2020 ESPP, eligible team members of the Company may elect for payroll deductions to purchase shares on each purchase date during an offering period. A total of 250,000 shares of common stock of BGSF, Inc. were initially reserved for issuance pursuant to the 2020 ESPP. All shares remain available for issuance as of March 28, 2021 and the Company began the initial offering period during second quarter 2021.